Table 2.
Association between race/ethnicity and incidence of MTX neurotoxicity among patients treated on acute lymphoblastic leukemia protocols, 2012-2017
| Patients at Baseline | Neurotoxic Events | Unadjusted Model | Adjusted Model1 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-val | HR (95% CI) | p-val | |||
|
|
||||||
| Race/Ethnicity | 100 | 8 | Ref. | Ref. | ||
| Non-Hispanic White Hispanic | 133 | 29 | 2.93 (1.34-6.42) | 0.01 | 2.43 (1.06-5.58) | 0.036 |
| Non-Hispanic Black | 23 | 2 | 1.15 (0.24-5.40) | 0.86 | 1.23 (0.25-5.91) | 0.80 |
| Non-Hispanic Other | 20 | 0 | -- | -- | -- | -- |
1
Model adjusted for treatment risk arm, age at diagnosis, BMI z-score at diagnosis, and sex